Researchers at the University of Reading have developed a diagnostic test that identifies effective antibiotics for urinary tract infections within hours. Published March 31 in the Journal of Antimicrobial Chemotherapy, the study marks a significant departure from traditional culture methods. This innovation aims to reduce patient suffering and combat rising antimicrobial resistance globally. The team worked with the University of Southampton and Hampshire Hospitals NHS Foundation Trust.
The new protocol delivers results in approximately 5.85 hours, a drastic improvement over standard laboratory timelines. Current practices typically require two to three days to cultivate bacteria and determine susceptibility. This acceleration allows clinicians to prescribe targeted therapies before infections worsen significantly. Such speed is critical for preventing complications that lead to severe sepsis.
Testing evaluated 352 urine samples from patients suspected of having infections across seven antibiotics. The new method matched standard laboratory results in 96.95% of cases. A secondary analysis of 90 duplicate samples confirmed high reliability regardless of preservative use. The data suggests the technology is viable for routine clinical settings.
Key Details
"By the time the laboratory delivers the result under current methods, a patient may already have finished their antibiotics, or been given ones that do not work," said Dr. Oliver Hancox. The Chief Executive Officer of Astratus Limited emphasized that same-day results reduce resistance risks. He noted this could prevent infections from turning into potentially lethal sepsis. The quote underscores the economic burden of ineffective treatments.
NHS data indicates urinary tract infections resulted in more than 800,000 hospital admissions in England over the past five years. Approximately one in four urine samples tested in NHS laboratories contains bacteria resistant to commonly used drugs. Around 65 million urine samples are analyzed annually within the United Kingdom alone. These figures highlight the urgent need for faster diagnostic tools.
The system eliminates the need for overnight culturing by placing urine directly into a cartridge. Small tubes preloaded with antibiotics are inserted into an instrument for optical imaging. The device monitors bacterial growth to determine if the specific drug remains effective for the patient. This direct-from-urine approach simplifies the workflow for laboratory staff.
"Getting the right treatment first time could be a lifesaver," said Professor Matthew Inada-Kim. He serves as a consultant acute physician and AMR Lead at Hampshire Hospitals NHS Foundation Trust. The researcher highlighted that this tool changes how medical teams manage infections in practice. Clinical efficacy remains the primary focus of this development.
Researchers conducted a unique experiment comparing fresh samples against those preserved with boric acid. They found 98.75% agreement between preserved and unpreserved results. This validation ensures the test works with standard collection protocols used in emergency departments. The study represents the first direct comparison of preserved samples using this method.
Astratus Limited, a University of Reading spin-out, established in November 2024 to commercialize the technology. The National Institute for Health and Care Research funded the initial development. Professor Mike Lewis described the project as a real-world solution to antimicrobial resistance. Commercialization efforts are now underway to bring the device to market.
What This Means
Widespread adoption could significantly lower hospitalization costs and improve public health outcomes. Global health organizations are prioritizing rapid diagnostics to mitigate the threat of superbugs. Next steps involve scaling production and seeking regulatory approval for international distribution. The impact on global health security remains a key metric for success.
